Archives de la catégorie molecular diagnostic

Arnold Munnich

Dans Le Point du 17 octobre 2013, p 74-75, une mise au point d’Arnold Munnich (responsable du département de génétique de l’hôpital Necker-Enfants malades à Paris), titrée « La médecine n’est pas le tiercé ». Les propos sont recueillis par Jérôme Vincent qui signe également l’encadré de la p 75 sur « ce qui est autorisé, ce qui est interdit ». Excellent pour une prise de bec !
NB le dossier du Point est à lire, les autres intervenants semblent avoir les pieds sur Terre, aux kiosques !

D’abord, cartes sur table, je travaille pour Portable Genomics Inc., une société américaine, démarrée par des francais éxilés aux USA (à cause de l’ineptie qu’est la loi bioéthique française), et dont le business est lié cet espace de la génétique et de la génomique personnelle.

Avant une dissection en règle de cette mise au point deux choses que je souhaite clairs :

– Effectivement, la médecine, ce n’est pas le tiercé. Je suis entièrement d’accord.
– La génétique personnelle n’est pas le tiercé non plus; elle demande des médecins capables d’exploiter les connaissances actuelles et justement, pour éviter le tiercé,  je ne laisserai jamais un médecin comme Munnich s’occuper de moi ou des gens auxquels je tiens.



Lire la suite »

9 Commentaires

The Tables serie: Table 1-Highly Integrated Molecular Diagnostic Platforms

This is the 1st table of a serie of 3 on automated platforms in Molecular Diagnostics that will be available exclusively at Coffee And Sci(ence).  You can find it here:
Table 1-Highly Integrated Molecular Diagnostic Platforms 
Back in 2004, when Roche Molecular Diagnostics had introduced the Cobas Ampliprep + Cobas Taqman 48 in Europe, there was not too much instruments capable of such integration of nuclec acid extraction (NA) and realtime PCR (rtPCR) detection. Now (Nov. 2007), there is a bunch of them. Abbott, BD, Biomerieux, Cepheid, Gen-Probe, HandyLab, Iquum, Qiagen, Roche Diagnostics and Siemens Medical Solutions Diagnostics. If you are not here, please contact us.
Integration is essentially coming from the combination of 2 instruments, 1 for NA extraction, one for rtPCR. Abbott, Biomerieux, Roche and Siemens are the majors. They basically use Tecan, Hamilton, PSS based platforms for NA extraction combined with a rtPCR thermocycler from AB, former Organon-Teknika, Roche, Stratagene. Transfer of sample between instruments is manual, except for Roche who has produced the Docking Station, a robotic interface whichacts as a PCR plate conveyor.
I have mentionned Qiagen in this table because they have so much NA extraction platforms available and a long list of Molecular Diagnostic (MDX) reagents. However, Qiagen is still missing a rtPCR platform. Artus Biotech, before their acquisition by Qiagen, had a collaboration with Corbett Research around the RotorGene 3000. But Qiagen is not mentionning this partnership anymore. Hopefully they are on the market to find a solution.
Gen-Probe and BD have a different approach in that sense they are fully integrated instruments in a single box. Gen-Probe’s Tigris is the precursor of such category of instruments. Respect for that. But come on, this is a « Qual » platform, not a Quant. BD’s Viper is almost of a same age, however, BD has added very recently this fully integrated capacity to the Viper which is now capable of sample prep, SDA setup, and detection. But the specs of this later are still unclear. There is no mention at all of this platform in the real world, except in meetings and on BD’s booth. Is that rtSDA? I’m not sure.
Finally, a more recent category of platforms, the benchtop fully integrated MDX platforms, with Cepheid, Iquum and HandyLab. Cepheid is here the precursor with the GeneXpert4. They recently launched the GX1 and GX16 which are the younger and bigger bros of the GX4. Iquum is working on its Lab-in-a-tube technology since 2004. Hopefully we’ll see the Liat available soon. HandyLab has shown more recently their PCR chip based technology within their upcoming Jaguar platform.
Whoever will succeed the best, Cepheid, HandyLab and Iquum are clearly building the future of MDX platforms. Nanosphere’s Verigene system who has recently been approved by the FDA for various MDX assays, may also be part of the game. See this blog elsewhere, and remember Nanosphere is not using anymore PCR steps. 

, , , , , , , , , , ,

1 commentaire